Effect of Tolvaptan on Mid- to Long-term Prognosis of Heart Failure Patients

Heart Failure Clinical Trial

Official title:

A Multi-center,_double-blind,_pararel-group Comparison Trial to Investigate the Effect of Short-term Administration of Tolvaptan on Mid- to Long-term Prognosis of Heart Failure Patients (Phase_4 Study)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01439009
• Other study ID #: 156-10-005
• Secondary ID: JapicCTI-111621
• Status: Completed
• Phase: Phase 4
• Start date: September 2011
• Est. completion date: March 2014

Study information

• Verified date: October 2019
• Source: Otsuka Pharmaceutical Co., Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

One tolvaptan 15 mg tablet or placebo tablet will be orally administered once daily in the morning for up to 14 days to heart failure patients with volume overload that does not show adequate response to other diuretics such as loop diuretics in order to investigate the effect of tolvaptan on the mid- to long-term prognosis of the target population. The efficacy of tolvaptan during the treatment period will also be investigated.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 100
• Est. completion date: March 2014
• Est. primary completion date: March 2014
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years to 85 Years

Eligibility

Inclusion Criteria:

• Patients from whom informed consent has been properly obtained in writing prior to start of the trial

• Patients who have been clinically diagnosed with heart failure

• Patients with any of the following conditions or symptoms: lower limb edema, dyspnea, jugular venous distension, hepatomegaly, pulmonary rales, third heart sound, or pulmonary congestion

• Patients who have been receiving loop diuretics, thiazide diuretics, or anti-aldosterone diuretics

• Male or female patients of age 20 to 85 years inclusive (at time of informed consent)

• Patients who, together with their partner(s), are able to use an appropriate method of contraception until 3 months after final trial drug administration

• Patients who are able to be hospitalized at the trial site for at least 7 days from the start of trial drug administration

Exclusion Criteria:

• Patients with a history of hypersensitivity to any ingredient of the drug or to tolvaptan analogues (e.g., mozavaptan hydrochloride)

• Patients with anuria

• Patients who cannot sense thirst or who have difficulty with fluid intake

• Patients with hypernatremia (serum sodium concentration > institutional upper limit of normal) 5) Female patients who are pregnant, possibly pregnant, or nursing

• Patients judged by the investigator or subinvestigator to be inappropriate for inclusion in the trial due to any of the following conditions or symptoms:

• Hyponatremia (serum sodium concentration < 125 mEq/L)

• Serious coronary artery disease or cerebrovascular disease

• Hyperkalemia

• Severe renal disorder

• Poorly controlled diabetes mellitus

• Severe hepatic disease

• Impaired urinary excretion due to urinary stenosis, calculus, or tumor

• Cardiac valve disease with significant heart valve stenosis

• Malignant tumor of unfavorable prognosis

• Patients with suspected hypovolemia

• Patients with an implanted circulatory support device

• Patients in whom acute cardiac infarction occurred within 30 days prior to the screening examination

• Patients who participated in any other clinical trial or postmarketing clinical trial within 30 days prior to the date of informed consent for the present trial

• Patients who received tolvaptan within 26 weeks prior to the date of informed consent

• Patients who are otherwise judged by the investigator or sub-investigator to be inappropriate for inclusion in the trial

Related Conditions & MeSH terms

• Heart Failure

Intervention

Drug:
• Tolvaptan
Once-daily oral administration of one tolvaptan 15 mg tablet in the morning
• Placebo of tolvaptan
Once-daily oral administration of one placebo tablet in the morning

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Otsuka Pharmaceutical Co., Ltd.

Country where clinical trial is conducted

Japan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Cummulative Incidence of Events at Week 26	From start day of IMP administration to final day of follow up period, 1) and 2) below were defined as event; Death from cardiovascular events; Worsening of heart failure; The day of re-hospitalization due to worsening of heart failure; The day of medication below due to worsening of heart failure Phosphodiesterase III inhibitors (Injection), Catecholamine preparations (Injection), Colforsin preparations (Injection), Diuretics (Injection), Human atrial natriuretic peptide preparations (Injection):Calperitide (Injection)	Week 26
Primary	Mortality (Number of Death)	Statistical comparison was not done.	Week26
Primary	Body Weight	The comparison of the average of amount of change from baseline. Statistical comparison was not done.	Day15
Primary	Number of Subjects Whose Lower Limb Edema Severity Grading Improved by One or More Grade	Of the subjects who had lower limb edema at baseline, the number of subjects whose lower limb edema severity grading. Statistical comparison was not done.	Day15
Primary	Jugular Venous Distension	The comparison of the average of amount of change from baseline. Statistical comparison was not done.	Day15
Primary	Change in Liver Size From Baseline	The comparison of the average of amount of change from baseline. Statistical comparison was not done.	Day15
Primary	Pulmonary Rales	Of the subjects who had pulmonary rales at baseline, the number of subjects whose symptom was resolved at completion of treatment. Statistical comparison was not done.	Day15
Primary	Third Heart Sound	Of the subjects who had third heart sound at baseline, the number of subjects whose symptom was resolved at completion of treatment. Statistical comparison was not done.	Day15
Primary	Cardiothoracic Ratio	Investigator majored Thoracic length and Cardiac length from chest X-ray. Cardiothoracic Ratio was calculated from Cardiac length/Thoracic length*100. Lowering of Cardiothoracic Ratio suggests recovery from heart congestion.; The comparison of the average of amount of change from baseline. Statistical comparison was not done.	Day15
Primary	Pulmonary Congestion	Of the subjects who had pulmonary congestion at baseline, the number of subjects whose pulmonary congestion severity grading showed an improvement of one grade or more (eg, moderate to mild) at completion of treatment. Statistical comparison was not done.	Day15
Primary	Plasma Brain Natriuretic Peptide (BNP) Concentration	The comparison of the average of amount of change from baseline. Statistical comparison was not done.	Day15
Primary	Dypnea	Of the subjects who had dyspnoea at baseline, the number of subjects whose symptom was resolved at completion of treatment. Statistical comparison was not done.	Day15
Primary	Number of Subjects Whose New York Heart Association (NYHA) Classification Improved by One More Grade From Baseline	New York Heart Association (NYHA) Classification is below ClassI:No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, dyspnea (shortness of breath).; ClassII:Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea (shortness of breath).; ClassIII:Marked limitation of physical activity. Comfortable at rest. Less than ordinary activity causes fatigue, palpitation, or dyspnea.; ClassIV:Unable to carry on any physical activity without discomfort. Symptoms of heart failure at rest. If any physical activity is undertaken, discomfort increases.	The day after last IMP administration and Baseline